Since the Food and Drug Administration (FDA) approved voretigene neparvovec-rzyl (Luxturna™) from Spark Therapeutics roughly one year ago, patients with inherited retinal dystrophies (IRDs) have been given reason to believe they may see light at the end of their darkening prognosis. Two clinician scientists studying IRDs offer their perspectives on the scientific and clinical challenges that still face their field and patients.
Inventor. Co-founder. Graduate student. Lucinda Camras, PhD, chief scientific officer of Camras Vision, can claim all of these titles. Camras shares with ARVONews some insights into her company’s ambitious beginnings and products.
The 2017 Dr. David L. Epstein Award was presented to David Huang and Liang Liu. With support from the award, Huang and Liu are examining the application of OCT angiography as a diagnostic and monitoring tool for glaucoma.
Cameroonian ophthalmologist Jeanne Mayouego Kouam, MD, received an important and career-changing email. She learned she was a recipient of the ARVO Foundation’s Developing Country Eye Researcher Travel Fellowship.
The pool of researchers that have received travel grants has proven to be fertile ground for cultivating new engaged leaders.
ARVO launches new International Advocacy Toolkit assisting members across the globe who are interested in influencing vision research funding and policy in their home country.
Learn tips and advice from Stella Robertson, PhD, who helps entrepreneurs and start-ups launch and grow emerging technology companies.
ARVO President Steven J. Fliesler, PhD, FARVO, shares why he chose the theme of ARVO 2019 'From bench to bedside and back'.
From our series 5 members in 5 minutes, what’s the key to developing a successful abstract submission? Members with high-scoring ARVO Annual Meeting abstracts offer their best tips and advice.
Mark F. Bear, PhD, received the 2018 Beckman-Argyros award for his research on the fundamental mechanisms of synaptic plasticity in the brain, the synaptic and molecular basis for the effects of monocular deprivation and patch therapy, and the role of experience-dependent synaptic plasticity in learning, memory and neurorehabilitation.
The ARVO Foundation Chair Paul Sternberg, Jr., MD, FARVO, highlights how its mission shines through at ARVO 2018 in Honolulu.
From travel grantee to leadership development. Ten years after receiving her first ARVO Foundation travel grant, Allen M. Y. Cheong, PhD, participated in another initiative: the Leadership Development Program for Women in ARVO for early- to mid-career female vision scientists.
ARVO Travel Grant recipients share how the funding impacted their careers
The activities of this past year’s science communications fellows provide great examples of how scientists can share the value of their research with the community at large.
Introducing ARVO’s enhanced online learning system, ARVOLearn, which provides an easy-to-use online experience for ARVO members and others in the eye and vision science field.
ARVO is a truly international organization with a geographic diversity reflected in its journals. Over the past two years, ARVO journals have included authors from 97 countries. View graphs illuminating trends and new patterns.
Looking toward the next 50 years
Since the Food and Drug Administration (FDA) approved voretigene neparvovec-rzyl (LuxturnaTM) from Spark Therapeutics roughly one year ago, patients with inherited retinal dystrophies (IRDs) have been given reason to believe they may see light at the end of their darkening prognosis.
Seven scientists recognized for the first successful gene therapy to cure an inherited human disease
